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Background: Farnesyltransferase inhibitors (FTIs) are anticancer agents with a spectrum of activity in Ras-dependent
and independent tumor cellular and xenograph models. How inhibition of protein farnesylation by FTIs results in
reduced cancer cell proliferation is poorly understood due to the multiplicity of potential FTase targets. The low toxicity
and oral availability of FTIs led to their introduction into clinical trials for the treatment of breast cancer, hematopoietic
malignancy, advanced solid tumor and pancreatic cancer treatment, and Hutchinson-Gilford Progeria Syndrome.
Although their efficacy in combinatorial therapies with conventional anticancer treatment for myeloid malignancy and
solid tumors is promising, the overall results of clinical tests are far below expectations. Further exploitation of FTIs in
the clinic will strongly rely on understanding how these drugs affect global cellular activity.
Methods: Using FTase inhibitor I and genome-wide chemical profiling of the yeast barcoded deletion strain collection,
we identified genes whose inactivation increases the antiproliferative action of this FTI peptidomimetic. The main
findings were validated in a panel of cancer cell lines using FTI-277 in proliferation and biochemical assays paralleled by
multiparametric image-based analyses.
Results: ABC transporter Pdr10 or p-21 activated kinase (PAK) gene deletion increases the antiproliferative action of
FTase inhibitor I in yeast cells. Consistent with this, enhanced inhibition of cell proliferation by combining group I PAK
inhibition, using IPA3, with FTI-277 was observed in melanoma (A375MM), lung (A549) and colon (HT29), but not in
epithelial (HeLa) or breast (MCF7), cancer cell lines. Both HeLa and A375MM cells show changes in the nuclear
localization of group 1 PAKs in response to FTI-277, but up-regulation of PAK protein levels is observed only in
HeLa cells.
Conclusions: Our data support the view that group I PAKs are part of a pro-survival pathway activated by FTI
treatment, and group I PAK inactivation potentiates the anti-proliferative action of FTIs in yeast as well as in cancer cells.
These findings open new perspectives for the use of FTIs in combinatorial strategies with PAK inhibitors in melanoma,
lung and colon malignancy.
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Farnesyltransferase inhibitors (FTIs) are broad-spectrum
low-toxicity anticancer agents originally isolated from
fungi to inhibit Ras oncoprotein membrane attachment
and therefore their malignant transforming activity [1,2].
The FTI Manumycin A was the first to be selected using
a yeast-based genetic screen [3,4]. More than two de-
cades of studies, using structurally different FTI com-
pounds tested on several tumor cell lines, xenograph
and cancer animal models, have confirmed that they act
via evolutionarily-conserved mechanisms by inhibiting
farnesyltransferase activity [1,2,5-7]. Surprisingly, FTIs
were found to be effective also in Ras-independent
tumors. Despite several studies, how FTIs act as anti-
replicative compounds remains to be fully elucidated: hun-
dreds of proteins are farnesylated in human cells, among
which are several proteins activating pro-survival pathways.
Inhibition of farnesylated proteins such as RheB or CENP-
E appears to be among the consolidated data for some
non-Ras tumors sensitive to FTIs. Complicating this pic-
ture, recent data suggest that farnesylation-independent
pathways might also participate in the anticancer activity
of FTIs [8-10].
Despite this lack of knowledge, the low toxicity of FTIs
for normal cells and their wide-range of high anti-
proliferative action on tumor cells led to the introduc-
tion of orally-available FTI molecules into clinical trials
[5,6,11]. The FTI Tipifarnib (Zarnestra, R115777) has
been evaluated for the treatment of myeloid malignancy,
including for elderly patients with acute myelogenous
leukemia (AML) [6,12]. Moreover, Tipifarnib has shown
promising results in coadjutant therapies for breast can-
cer [13]. The FTI Lonafarnib have shown efficacy in
melanoma cells that develop resistance to Sorafenib, a
pan-Raf inhibitor [14]. The poor performance of FTIs at
the clinical level compared to their anticipated wide use
in anticancer therapy clearly shows the weakness of the
mechanistic studies performed thus far. The further ex-
ploitation and future introduction of FTIs into clinical
therapy will largely depend on the identification of com-
pounds that increase FTI antiproliferative action in re-
sistant tumors and on the identification of susceptibility
prediction markers [5,6,11].
The major limitation of proteomic approaches under-
taken thus far devoted to clarifying which farnesylated
proteins are differentially prenylated upon FTI treatment
has been the difficulty of correlating the effective protein
prenylation status with their anti-proliferative action
[5,6]. Several types of genomic technologies have been
used to identify predictive markers/pathways that could
explain how FTIs affect cellular activity and responsive-
ness. A handful of genes has been identified whose func-
tion might lead to FTI resistance [6,15-17]. Lack of FTI
responsiveness has been shown to result from innate oracquired resistance or from FTI-mediated activation of
pro-survival pathways. In addition, mutation of FTase or
target genes, activation of alternative prenylation pathways,
or changes in the balance of prenylated proteins have been
described extensively upon FTI treatment [5,6,11].
To identify the major protein networks responding to
FTI peptidomimetics as well as the major pathways that
allow an escape from the anti-proliferative action of FTIs
in yeast and mammalian tumor cell lines, we used bud-
ding yeast cell-based “omic” approaches and then vali-
dated the main findings in mammalian cancer cell lines.
Well-characterized structurally related FTI compounds
that are active in yeast or in mammalian cells, FTase in-
hibitor I and FTI-277, respectively, were used in order to
compare the data. We expect that the basic knowledge
obtained by these studies will give a better view of how
to use clinically useful FTIs in combinatorial therapies.
With this long-term goal in mind, in a previous study
we profiled gene expression upon FTase inhibitor I treat-
ment of yeast cells. Transcriptional and localization
changes of P-glycoproteins belonging to the ABC trans-
porter family acting in sphingolipid metabolism and
drug resistance were observed [10]. Other transcriptional
changes were found for genes encoding proteins that act in
key signal transduction pathways regulating cell cycle entry
and chromosome segregation and nutritional cues. We
showed that these effects were specific to FTase inhibitor I
(not being related to GGTase I inhibition or FTase subunit
gene deletion in yeast cells). Multiparametric functional
studies were carried out in HeLa cells to validate these ob-
servations. Nuclear morphology, Aurora A localization and
S6 phosphorylation were found to be affected by FTI-277
treatment of HeLa cells [10]. Collectively these findings
showed that FTIs have several unexpected effects on sig-
naling pathways regulating proliferation that are not dir-
ectly related to farnesylation and that these effects could be
reciprocated in HeLa cells.
To identify genes whose deletion increases the anti-
proliferative action of FTI peptidomimetics, here we report
the chemical-genetic profiling of the yeast Saccharomyces
cerevisiae barcoded deletion strain collection using FTase
inhibitor I. Two p-21 activated kinases (PAKs), Cla4 and
SKM1, and the ABC transporter Pdr10 were among the
genes whose deletion increased FTI sensitivity in yeast
cells. To test whether PAK inhibition might increase FTI
sensitivity in cancer cell lines resistant to FTIs, we mea-
sured the proliferation of HeLa, melanoma (A375MM),
lung (A549), colon (HT29) and breast (MCF7) cancer cell
lines after FTI-277 treatment, administrated alone or in
combination with a highly selective group I PAK inhibitor,
named IPA3 [18,19]. We show that the use of IPA3 at con-
centrations ranging from 5 to 7 μM in combination with
5 μM FTI-277 potently inhibits proliferation of A375MM
melanoma, A549 lung and HT29 colon cancer cell lines,
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cancer cell lines.
Results
The ABC transporter Pdr10 and p-21 activated kinases act
in pro-survival pathways mediating FTI peptidomimetic
susceptibility in yeast cells
To identify genes promoting survival to FTI peptidomi-
metic treatment in eukaryotic cells, we performed a
genome-wide drug sensitivity screen using the barcoded
yeast deletion mutant collection (representing approxi-
mately 4700 genes) and 10 μM of the peptidomimetic
FTase inhibitor I (Calbiochem-MERK). We have shown
previously that 10 μM FTase inhibitor I treatment of
BY4741 cells induces specific changes in the yeast tran-
scriptome without affecting Ras binding to the plasma
membrane [10].
The genome-wide sensitivity screen highlighted
sixty-four genes whose deletion results in a two-fold
increase in FTI sensitivity (log2 ratio > 0.5, p-value < 0,05;
Additional file 1: Table S1). These sixty-four hits were fur-
ther classified according to Gene Ontology criteria using
the Super GO-Slim Process clustering tool available at the
GO-SGD database (www.yeastgenome.org). This analysis
showed that 25% of the genes promoting survival to
FTI peptidomimetic treatment act in transport and
15.6% are annotated as being involved in cell cycle pro-
cesses (Figure 1A; Additional file 2: Table S2). The
functional associations among the hits involved in
transport were further analysed using STRING (version
8.3, http://string.embl.de/). This analysis showed that
Pdr10, an ATP-binding-cassette (ABC) transporter be-
longing to the multidrug resistant (MDR) gene class,
and the PAKs CLA4 and SKM1 form a gene network
with the ABC transporter PDR5 and the PDR transcrip-
tional regulator PDR1 (Figure 1B).
We showed previously that PDR5 and PDR1 are tran-
scriptionally up-regulated and that Pdr5 recycling in-
creases in FTase inhibitor I-treated yeast cells [10].
Moreover, Pdr5 recycling depends on END4 [20], which
interacts with the PAK Cla4p [21], suggesting the exist-
ence of a functional network that connects PDR5 recycling
at the plasma membrane and PDR1 transcriptional up-
regulation upon FTI drug treatment with increased sensi-
tivity in the presence of a CLA4 or PDR10 gene deletion.
To test this idea, we determined the levels of Cla4p
and its state of phosphorylation in yeast cells expressing
a GFP-tagged version of Cla4 (GFP-Cla4) treated with
FTase inhibitor I. GFP-Cla4 localizes like the wt protein
when expressed in BY4741 cells (Additional file 3: Figure
S1). Total lysates prepared from GFP-CLA4-transformed
cells treated with FTase inhibitor I (Figure 1C, lanes
FTI +) or left untreated (Figure 1C, lanes FTI -) were
immunoprecipitated (IP) using an anti-GFP antibody(αGFP) followed by immunoblot analysis. Total lysates
were prepared in the presence (Figure 1C, lanes PPA +) or
absence of λ-phosphatase (Figure 1C, lanes PPA –). After
normalization against the total amount of Cla4p present
in each sample, the amount of phosphorylated Cla4p was
calculated (Figure 1D). An average (n = 3) increase of 50%
in phosphorylated Cla4p was observed in FTase inhibitor
I-treated samples (Figure 1C, lanes FTI + PPA -) com-
pared to controls (Figure 1C, lanes FTI – PPA -).
Thus, we concluded that FTase inhibitor I treatment pro-
motes activation of the PAK kinase Cla4p in yeast cells.
FTI-277 promotes group I PAK expression in HeLa but not
in A375MM cells
PAK kinases are serine/threonine protein kinases that
are activated in response to various signalling pathways
that regulate proliferation, cell shape and motility in
mammalian cells. PAK protein levels have been corre-
lated with proliferation in several human tumors and are
known to participate in metastatic processes [22,23].
However, how PAK function relates to FTI efficacy has
never been investigated. Human PAKs can be subdivided
into two main classes based on their structural charac-
teristics. The current classification separates the yeast
PAKs (Cla4, Ste20 and Skm1) from both mammalian
PAK classes. However, based on complementation stud-
ies performed with PAK family members expressed in
ste20 mutants, the yeast PAKs are considered to be func-
tionally related to group I PAKs [23-25]. Therefore, to
determine the effects of FTI on PAKs in tumor cells we
first assayed the levels of group I PAKs in HeLa and
A375MM melanoma cell lines. HeLa and A375MM were
used in these studies as prototypical cancer cell lines
with different genotypes (Table 1) [26].
We first measured the basal levels and phosphoryl-
ation of group I PAKs and their cytosolic/nuclear distri-
bution in these cell lines upon FTI-277 treatment by
automated fluorescence microscopy-based high-content
phenotypic profiling using the acquisition and analysis
platform of the microscopy station ScanR (OLYMPUS).
In these series of experiments the group I PAK and
phosphorylated PAK protein levels were evaluated based
on the fluorescence intensity using anti-PAK-C19 (αPak)
or anti-phosphorylated PAK 1/2/3 [Thr423] (αPhoPak)
primary antibodies and appropriately fluorescently-
conjugated secondary antibodies, as previously described
[10]. These experiments were paralleled by immunoblot
analysis for independent validation. We chose to analyse
the cells 4 h and 48 h after FTI treatment because these
time points could be paralleled by proliferation studies.
Image analysis showed that group I PAKs and their phos-
phorylated forms, hereafter named PAKs and PhoPAKs, re-
spectively, localize in the cytoplasm as well as in the
nucleus of HeLa cells (Figure 2A and E, respectively), as
Figure 1 p-21 activated kinases or ABC transporters are among the genes whose deletion increases FTI sensitivity of yeast cells. A. Pie
visualization of the 64 genes identified by drug sensitivity screening as putative hits. Super GO Slim tool Biological Process Binning was used for
clustering the FTI hypersensitive hits. B. The network analysis of hypersensitive strains carrying deletions of CLA4, SKM1, PDR10 was performed for
known and predicted protein-protein interactions using STRING (http://string-db.org/). The evidence view is shown, different line colors represent
the types of evidence for the association. High confidence (score 0.700) excluding the text mining settings were used as parameters. C.
Immunoblot analysis of the immunoprecipitates obtained from BY4741 cells expressing GFP-Cla4. αPhoSer = anti-phosphoserine Q5 antibody;
αGFP = anti-GFP antibody. (+) indicates addition, (−) no addition. PPA = phosphatase lambda. FTI = 10 μM FTase I inhibitor. Numbers indicate MW.
Expected protein positions are indicated. D. The graph shows the relative amount of phosphorylated versus unphosphorylated Cla4 relative to
vehicle. The relative protein levels are expressed in percentage (%). The amount of control (vehicle-treated cells) was considered as 100%. Error
bars indicate means ± SD of at least 3 replicates (n = 3).
Table 1 Panel of tested tumor cell lines
Cell line Tumor type Genotype FTI sensitivity Source References
HeLa Cervical p53 not expressed Resistant ECACC [27]
A375MM Melanoma BRafV600E Resistant [28,29] [28-30]
HT29 Colon BRafV600E Sensitive ATCC [26,31,32]
p53R273H
A549 Lung KRasG12S Sensitive ATCC [33]
MCF7 Breast PI3KCAE545K Sensitive ATCC [34]
Note: wt genes are not indicated.
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Figure 2 FTI-277 treatment of HeLa cells up-regulates PAKs and phosphorylated PAKs. The statistical significance of the treatments was
calculated using t-test: ns = not significant, p-value >0.05; * = significant, p-value <0.05; ** highly significant = p-value <0.01). n = n. of biological
replicates. Each biological replicate consider the average mean intensity data obtained from analysis of three wells per condition. A. Fluorescently
stained HeLa cells treated for 48 h with the indicated concentration of FTI-277 or DMSO (Vehicle). Panels: PAK = anti-PAK (C19) antibody; Hoechst =
nuclear staining; Merge = Hoechst + PAK; Mask: software mask that identifies nuclear PAKs (green), and PAK clusters (spots) within nuclei (red). scale
bar =10 μm. B. The graph shows the relative amount (%) of PAKs in the nuclei in 4 h FTI277-treated cells relative to vehicle, arbitrarily set as 100%. C.
The graph shows the relative amount (%) of total PAKs in 48 h FTI-277-treated cells compared to vehicle-treated cells; D. Immunoblot analysis of total
lysates from HeLa cells treated as indicated in C. E. Fluorescently stained HeLa cells treated for 48 h with the indicated concentration of FTI-277 or
DMSO (vehicle). Panels: PhoPak = α-Phospho-PAK1/2/3[pThr423] antibody; Hoechst = nuclear staining; Merge = Hoechst + PhoPak; Mask: software
mask that identifies nuclear PhoPaks (green), and PhoPak clusters (spots) within nuclei (red). F. The graph shows the relative amount (%) of total
PhoPaks in 4 h FTI277-treated cells relative to vehicle-treated cells. G. The graph shows the relative amount of total PhoPaks in 48 h FTI277-treated cells
compared to vehicle-treated cells; H: immunoblot analysis of total lysates form HeLa cells treated as in G. I. The graph shows the relative number (%) of
PhoPaks spots within the nuclei in 48 h FTI277-treated cells relative to vehicle-treated cells, which were arbitrarily considered 100%.
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spots of different dimensions in the nucleus (Figure 2A and
E, respectively). After 4 h treatment with 5 μM or 15 μM
FTI-277, this localization did not change substantially, nor
were PAK protein levels affected (Figure 2B) although a
slight decrease in the PhoPAK signal was observed
(Figure 2F). By contrast, after 48 h of 5 μM FTI-277 treat-
ment, a significant (p ≤ 0.01 n = 4) increase in the PAK
(Figure 2C) and PhoPAK signal (Figure 2G; p ≤ 0.01 n = 4)was observed. Immunoblot analysis of samples treated in
parallel experiments confirmed these trends (Figure 2D and
H, respectively). Moreover, a significant increase (p ≤ 0.05)
in PhoPAK clusters within the nuclei was observed
(Figure 2I).
We further compared the PAK and PhoPAK
localization in HeLa and A375MM cell lines treated
and untreated with FTI-277. We observed that PAK
localization differs significantly in these cell lines. In
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within the nuclei, while in HeLa cells only 77% of the
protein shows this localization (Figure 3A). Upon FTI-
277 treatment we failed to observe any effect on PAK
protein levels in A375MM melanoma cells. However, as
in HeLa cells, the PhoPAK clusters within the nuclei in-
crease significantly over control (Figure 3C panel PhoPak
clusters). These data indicate that although the majority of
PAK resides within the nuclei in A375MM cells, FTI-277
treatment causes a change from a diffuse to a clustered
state of this protein (Figure 3C) but does not affect the
overall amount of PAK protein, as occurs in HeLa cells.
To further investigate how FTI-277 treatment affects
PAK activity in HeLa cells, we investigated the cell adhe-
sion capabilities of treated versus control cells. It is well
established that the interaction of PAKs with the cyto-
solic PIX-GIT/Paxillin signaling module increases cell
motility by promoting focal adhesion (FA) turnover and
disassembly [23,25,38]. A way to estimate FA assembly isFigure 3 FTI-277 does not affect the localization of PAKs and PhoPAK
for 48 h as indicated in Figure 2 and in Methods, and stained with relevant
intensity of the fluorescent signal present in nuclei and in the whole cells.
nucleus versus the amount present in the whole cell in the indicated treat
(respective panels) present in nucleus versus the amount present in the wh
relative amount of PAKs, PhoPAKs, and PhoPAK clusters in A375MM cells tr
intensity of the signal in vehicle samples was arbitrarily considered 100%. T
normalized against the total number of cells counted. All graphs (panel A,
each run in triplicate (three wells per condition). The statistical significance
significant, p-value >0.05; * significant, p-value < 0.05; **** = highest significto estimate the amount of vinculin at membranes, as
vinculin reduction correlates with reduced FA formation
and increased cell migration rates [24,39,40]. Thus, we
determined the effects of FTI-277 on cell adhesion by
following vinculin recruitment to FAs in HeLa cells,
treated with 5 μM or 15 μM FTI-277 or with vehicle
using automated fluorescence microscopy on cells plated
in 96-well plates, fixed and processed for image analyses
as described above.
As expected, in vehicle-treated samples, vinculin clus-
ters at the membrane were observed, indicating FA for-
mation (Figure 4A panel Vehicle) [39]. Treatment with
5 μM or with 15 μM FTI-277 for 4 h resulted in an in-
creased number of FAs containing vinculin compared to
control samples (Figure 4B). The time of treatment did
not substantially affect this trend (Figure 4C). These data
indicate that although the overall PAK levels in HeLa
cells increase (Figure 2C and G), there are no affects of
the cytosolic PAK activity on FAs.s in HeLa and A375MM cells. HeLa and A375 MM cells were treated
antibodies. Olympus ScanR analysis software was used to calculate the
A. The graph represents the relative amount (%) of PAKs present in
ment. B. The graph represents the relative amount (%) of PhoPAKs
ole cell in the indicated treatment. C. The graph represents the
eated for 48 h as indicated in Figure 2 and in Methods. The mean
he amount of PhoPAK spots present in the nuclei of each sample was
B, C) shows the mean ± SD of at least 2 independent experiments,
of the indicated treatments was calculated using t-test: ns = not
ance, p-value <0.0001.
Figure 4 FTI-277 treatment of HeLa cells increases focal adhesions. A: The images show the localization of vinculin in FTI277-treated and
vehicle-treated samples together with the software mask to identify total vinculin (red) and vinculin at the focal adhesions (blue). HeLa cells were
treated as indicated in the text and stained for immunofluorescence analysis with α-vinculin primary and appropriate secondary fluorescently
labeled antibody, as indicated in Methods. To calculate the number of focal adhesions in each experiment at least 86 cells were counted per
sample. The software mask corresponding to the vinculin signal is highlighted (panel A, Mask, blue circled spots). The number of focal adhesions
present in each sample was counted and normalized against the total number of cells counted. The number of focal adhesions in vehicle
samples was arbitrarily considered 100%. The yellow scale bar represents 10 μM. B and C. The graphs show the mean ± SD of at least 2
independent experiments, each run in triplicate (three wells per condition) at the indicated time points.
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potent antiproliferative action in melanoma, lung and
colon cell lines
The large number of possible group I PAK activators in
proliferating cells [22], many of which remain unknown
[23], makes it difficult to identify proteins that might ac-
tivate group I PAKs in the nuclei of different cancer cell
lines. Therefore, we first focused on determining the ef-
fects of PAK inhibitors on the panel of cancer cell lines
listed in Table 1 using MTS-based proliferation assays.
MCF7 breast cancer, HT29 colon cell line and A549
lung cancer cell line are reported to be FTI-sensitive cell
line [19,26,41], while HeLa cervical and A375MM mel-
anoma cell line are reported to be resistant to FTIs
[14,26]. The PAK inhibitor IPA3, which targets the
Cdc42-mediated autophosphorylation of threonine 423
in group I PAK proteins, was used in these studies as it
is highly specific [42].
Proliferation tests were performed using a range of
concentrations of IPA3 previously shown to affect the
proliferation of different tumor cell lines [43]. In prelim-
inary tests we also determined the toxic concentration of
IPA3 in HeLa cells and A375MM cells. We observed
that although HeLa cells are fairly resistant to this com-
pound, 48 h treatment with 20 μM IPA3 is toxic for thiscell line (Additional file 4: Figure S2). Based on this, a
concentration of 2, 5, or 7 μM IPA3 was use in further
studies. To perform these experiments, HeLa, A375MM,
HT29, A549 and MCF7 cancer cell lines were left to at-
tach for 24 h in 96-well plates, treated with 5 μM FTI-
277 or with 2, 5, or 7 μM IPA3 administrated alone, or
with a combination of FTI-277 and IPA3. The cells were
then incubated for a further 48 h prior to data acquisi-
tion as described in Methods.
We observed that A549 cells and MCF7 cells were
sensitive to 5 μM FTI-277 (Figure 5), while the other cell
lines were not. All cell lines were sensitive to 7 μM
IPA3, HeLa and MCF7 cells being the most sensitive,
while A549, A375MM and HT29 cells show only moder-
ate sensitivity (Figure 5, respective panels). The com-
bined use of 7 μM IPA3 and 5 μM FTI-277 resulted in
the strongest inhibition of proliferation (p-value <
0.0001) in all cell lines, A375MM cells being the most
sensitive. However, it should be noted that the combin-
ation of 5 μM FTI-277 and 7 μM IPA3 did not substan-
tially change the basal sensitivity of HeLa and MCF7
cells observed using 7 μM IPA3 alone.
We concluded that inhibition of group I PAKs using
IPA3 combined to FTI-277 treatment potently inhibits
the proliferation of A375MM, A549 and HT29 cancer
Figure 5 Combined use of FTI-277 and PAK inhibitor IPA3 reduce proliferation of A375MM, HT29, A549 cells but not of HeLa or MCF7
cells. Effects of FTI-277 and/or IPA3 on cell proliferation in the indicated cells.% is relative to the vehicle that was considered as 100%. Error bars
indicate means ± SD of 3 independent experiments from 5 wells. The statistical significance of the treatments was calculated using t-test as
described in Methods: ns = not significant, p-value >0.05; * = significant, p-value <0.05; ** highly significant = p-value <0.01; *** very highly
significant = p-value < 0.001; **** highest significance = p-value < 0.0001.
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proliferation of HeLa and MCF7 cancer cell lines inde-
pendently of FTI treatment (Figure 5).
To determine if the different proliferative ability of
HeLa compared to A375MM cells in the presence of
5 μM FTI-277 and 7 μM IPA3 was due to an increase in
the number of apoptotic cells, we analyzed the percent-
age of cells that had fragmented nuclei using the ScanR
analysis software [10]. FTI-277 treatment of A375MM
cells led to a significant increase in the number of
apoptotic cells, which was reduced when the cellswere co-treated with IPA3, suggesting that IPA3 has a
protective effect against apoptosis (Additional file 5:
Figure S3, respective panels). These data indicate that
IPA3 counteracts the pro-apoptotic activity of FTI-
277 in this cell line. By contrast, no major effects
were observed on HeLa cells using either drug alone
or in combination (Additional file 5: Figure S3, respective
panels).
To estimate the number of senescent cells, we mea-
sured the mean area of cells compared to control [44]
after FTI-277 treatment in the presence or absence of
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software. We observed that the combined treatment of
FTI-277 and IPA3 resulted in a statistically significant
increase in the overall cellular area in both HeLa and
A375MM cells compared to vehicle-treated cells but not
compared to FTI-277 treated cells (Figure 6).Figure 6 Combined treatment of FTI-277 and IPA3, but not FTI-277 a
A375MM cells were treated for 48 h as indicated in Figures 2, 3 and in Met
software was used to calculate the area of each cell counted. The graph re
A375MM cells (respective panels) with cells treated with vehicle, arbitrarily
experiments, each run in triplicate (three well per condition). More than 73
sample in each experiment. Results of t-test are shown above the graph: n
nn: no significant deviation from FTI-277, p-value >0.05.Discussion
Group 1 PAKs are key players in cellular mechanisms that
are important for transformation, tumor progression and
metastatic processes [23]. Here we show that the com-
bined use of group I PAK inhibitors and FTI-277 exerts a
potent anti-proliferative action in melanoma, colon andlone, increases the cell size of HeLa and A375MM cells. HeLa and
hods, and stained with relevant antibodies. Olympus ScanR analysis
presents the relative area (%) of cells treated as indicated for HeLa and
set at 100%. The graph shows the mean ± SD of 2 independent
cells for A375MM and 573 cells for HeLa cells were counted per
s: no significant deviation from vehicle, p-value >0.05; * p-value <0.05;
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treatments of these tumors, these findings open the possi-
bility of using FTIs in combinatorial therapies with PAK
inhibitors for these aggressive tumors. Importantly, our
data show also that the underlying mechanism of how
PAK down-regulation and FTIs exerts an anti-proliferative
action on eukaryotic cells is evolutionarily conserved.
Our genome-wide FTI sensitivity screen data indicate
that deleting the ABC transporter gene PDR10 is one
way to increase FTI sensitivity in yeast cells. ABC trans-
porters constitute a large family of proteins that act as
detoxification pumps in yeast as well as in mammalian
cells [45]. They are known to participate in drug resist-
ance in various ways and to be up-regulated in several
tumors [20,45,46]. The data reported here support previ-
ous yeast genome-wide expression profiling studies
showing that the ABC transporter Pdr5 and its tran-
scriptional regulator Pdr1 respond to FTI drug intake in
yeast cells by up-regulating their activity [10]. Import-
antly it has previously shown that Pdr5 recycling from
the plasma membrane to endosomes depends on END4/
SLA1, which interacts directly with the PAK kinase Cla4
[20,21]. Recent epistasis studies indicate that Pdr10 has
a complementary function with Pdr5. Moreover, Pdr10
function depends on Pdr5, Pdr12, Lem3 and sphingo-
lipids [47-49]. Taken together these data, our expression
and chemical profiling of yeast cells treated with FTI in-
hibitor I, it can be envisaged that it exists a functional
network that connects FTI uptake at the plasma mem-
brane by ABC transporters acting in sphingolipid metab-
olism and PAK activation. Consistent with this, we
showed previously that FTase inhibitor I promotes Pdr5
recycling from the plasma membrane [10]. The existence
of a functional network that connects FTI uptake, ABC
transporter recycling and PAK activity is also supported
by the phenotypic analysis of yeast cells lacking of the
PAK CLA4 (Δcla4): a drastic reduction in drug resist-
ance and in the transcription of the ABC transporter
PDR5 was shown [47,50]. Here we show that the PAK
Cla4 is activated in FTase inhibitor I-treated yeast cells.
A role for some classes of the ABC transporter family in
FTI resistance in mammalian tumors has been previ-
ously suggested by genome-wide expression profiling
studies performed with the FTI Tipifarnib [8,9,17]. How-
ever, the large number of ABC transporters encoded by
the human genome, their different distribution in differ-
ent cancer cell lines, and their redundant functions [45],
makes it difficult to identify which of them might be
specifically involved in FTI uptake in the tumors studied
in this study.
The data obtained here indicate that in the presence of
FTI-277, PAKs sustain proliferation of melanoma, colon
and lung cancer cell lines, but unlikely of HeLa or
MCF7 cell lines. Proliferation inhibition caused by thecombined use of FTI-277 and IPA3 ranged from 40% for
HT29 cells to 68% for A375MM cells. In case of HT29
and A549 cells, even the lowest concentration (2 μM) of
IPA3 used significantly inhibited proliferation when
combined FTI-277 compared to IPA3 alone. The poor
response of HeLa and MCF7 tumor cell lines to the
combined use of the PAK inhibitor and FTI-277, com-
pared to the significant responsiveness of A375MM,
HT29 and A549 cell lines, must reside in the mechanism
that determines how FTI peptidomimetics act as anti-
proliferative drugs in these cell lines. A375MM and
HT29 are mutated in BRafV600 and A549 carry a K-Ras
mutation while HeLa cells have wt Ras. It is known that
A375MM cells rely on the activation of two main signal-
ing pathways that sustain proliferation: RAF-MEK-ERK
(MAPK) and PI3K-AKT-mTOR (AKT) signalling. The
FTI inhibitor Lonafarnib acts through inhibition of
mTOR signaling independently of MAPK or AKT activa-
tion [14]. Given these data it is conceivable that FTI-
mediated PAK activation acts in synergy with MAPK
and AKT pathways or is part of these pathways in these
cell lines. Thus not only the mechanism by which PAK
down-regulation exerts an anti-proliferative action in the
presence of FTIs must be a basic and well-conserved
process in the evolution, but also these data show that
the combined use of FTIs and PAK inhibitors potently
act as antiproliferative drugs in unrelated aggressive can-
cers characterized by constitutive activation of MAPK
and AKT pathways. This latter view is also supported by
the recently reported function of PAK1 in stimulation of
colorectal proliferation by gastrins via multiple signalling
pathways involving activation of ERK, AKT, and β-
catenin [51]. Increased p21-activated kinase-1 expression
is associated with invasive potential in uveal melanoma
[52]. Thus, it is conceivable to think that the contempor-
aneous shut-down of either the RAF-MEK-ERK (MAPK)
or PI3K-AKT signaling pathway might at the basis of the
susceptibility of HT29, A375MM and A549 cells to FTI
and PAK inhibitors.
All together our mammalian data substantially confirm
the yeast data showing that PAK inhibition cooperates
with FTIs in inhibiting proliferation of eukaryotic cells.
The susceptibility of the A549 lung cancer cell line,
which harbours a K-Ras mutation, to the combined use
of IPA3 and FTI-277 is of particular interest, given the
aggressiveness of current treatments for lung cancer. It
has been previously shown that A549 cells treated with
FTI-277 are blocked at the G2/M transition [19]. Inter-
estingly, it was observed that antibodies developed
against a specific C-terminal Ste20/PAK homologue fa-
cilitates the release of Xenopus oocytes from G2 arrest
[53]. Given the observation that a combination of FTI-
277 and IPA3 significantly increases the proportion of




Table 4 Antibody list
Name Manufacture/code Protein target










α-Actin Sigma, A2066 Actin
α-Vinculin, clone FB11 Chemicon, MAB1624 Vinculin
AlexaFluor 546 Goat Invitrogen, A11035 Rabbit IgG
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larly release A549 cells from the FTI-mediated G2/M
block and promote senescence. To try to answer why
the combinatorial use of IPA3 and FTI-277 does not re-
duce HeLa cell proliferation, we analysed the activation
status and the intracellular localization of PAKs in HeLa
and A375MM cell lines. However, none of the parame-
ters measured correlated with the different effects that
PAK inhibitors have on the respective proliferation abil-
ities. In HeLa cells the effects of FTI-277 on FA assem-
bly and vinculin recruitment are consistent with the
anti-proliferative function of FTIs and with the view that
cytosolic PAK/PIX/GIT module activation is not in-
volved in the FTI-mediated PAK activation response.
Conclusions
This work firmly establishes that PAK inactivation com-
bined with FTI treatment has a potent anti-proliferative
action on yeast as well as melanoma, colon and lung
cancer cells. Further work will be required to elucidate
how PAK inhibitors aid FTI anti-proliferative action in
these tumor cell lines. Based on the yeast data [10], we
suggest that ABC transporter recycling, consequent to
FTI uptake, is the initial signal that activate PAK.
Methods
Yeast strains, plasmid constructs, media and growth
conditions
Strains and oligonucleotides are listed in Tables 2 and 3,
respectively. Media, yeast transformation and genetic
manipulation as well as molecular procedures were as
described previously [54]. Unless otherwise specified,
yeast cells were grown at 28°C with agitation in YPD
medium or in SD medium lacking the appropriate
amino acid for plasmid selection as previously described
[54]. To construct GFP-tagged Cla4, the Cla4 ORF was
amplified by PCR from genomic DNA with the oligonu-
cleotides listed in Table 3 using the High Fidelity Poly-
merase Chain Reaction kit (Roche). The PCR product
was digested XmaI/EcoRI and ligated into the vector
pUG34 as described previously [54].
Reagents and antibodies
FTase inhibitor I (Cat.No 344510) and FTI-277 (Cat. No.
344555) were purchased from Merck-Calbiochem and
were used according to the manufacture’s protocols as
described in [10]. The p-21 activated kinase inhibitor IPA3Table 2 Strains
Strains Genotype Source
BY4741 wt MATa, leu2, ura3, his3, met15 EUROSCARF
Deletion strain collection
research genetics
MATa haploid deletion mutants [55](1,1′-Disulfanediyldinaphthalen-2-ol, Cat.No. I2285) was
purchased from Sigma. Antibodies are listed in Table 4.
Yeast protein extraction, immunoprecipitation and
immunoblot analysis
BY4741 cells carrying the plasmid GFP-Cla4 pUG34
were grown in the presence or absence of 10 μM FTase
inhibitor I in selective media as previously described
[10]. Typically, the drug was added to cultures diluted
to an OD600 = 0.08 and the cells were harvested at
OD600 = 0.6. To prepare crude extracts for phosphopro-
tein detection, the cells were diluted 1:1 in Stop Mix
(0.9% NaCl, 1 mM NaN3 10 mM EDTA, 50 mM NaF),
washed once in Stop Mix, and resuspended in Lysis
Buffer (50 mM Tris–HCl pH 7.5, 0.1 mM EDTA, 1 mM
DTT, 1 mM PMSF) containing protease inhibitor and
phosphatase inhibitor tablets (Roche) as described [56].
Crude extracts were obtained by the glass beads
method and glycerol was added to a final concentration
of 20%. The protein concentration was determined
using the Bradford assay as described [54]. Immunopre-
cipitation and immunoblot analysis were performed as
described previously [57]. Results were analysed and
quantified on a Pharos FX densitometer using the
Quantity One software (BioRad).
Drug sensitivity screening of yeast cells
The screen was performed using 10 μM FTase inhibitor
I on the barcoded yeast deletion strain collectionα-Rabbit IgG
AlexaFluor 546 Goat
α-Mouse IgG
Invitrogen, A11030 Mouse IgG
AlexaFluor 488 Goat
α-Rabbit IgG
Invitrogen, A11034 Rabbit IgG
AlexaFluor 488 Chicken
α-Mouse IgG
Invitrogen, A21200 Mouse IgG
Porcu et al. Molecular Cancer 2013, 12:88 Page 12 of 15
http://www.molecular-cancer.com/content/12/1/88generated by the S. cerevisiae deletion consortium [58]
for all genes whose deletion has a viable phenotype in
yeast. The screening was performed according to the
procedures and protocols described in [55]. The cut-off
for the hits was set at an average log2 ratio of 0.5 (p ≤ 0.05).
Gene clustering and classification was performed using the
GO Term tool of the SGD database (www.yeastgenome.
org). Binning by biological process was performed with a
maximal confidence setting as previously described [10].
Data mining was performed using NCBI databases (http://
www.ncbi.nlm.nih.gov/pubmed/). Gene network analysis
and network graphic representation was performed using
STRING (version 8.3) software that collects data from
known and predicted protein interaction databases freely
available at http://string.embl.de. The interactions include
direct (physical) and indirect (functional) associations;
they are derived from Genomic Context, High-throughput
Experiments, Coexpression Previous Knowledge. Confi-
dence setting for data analysis was set at 0.7 (high confi-
dence value).
Human cell culture and drug treatments
Media, serum and reagents for tissue culture were pur-
chased from GIBCO™ (Invitrogen). HeLa cells (ECACC)
were grown in MEM supplemented with 10% foetal calf
serum (FCS), 2 mM L-glutamine, penicillin, strepto-
mycin and non-essential amino acids, at 37°C in 5%
CO2. A375MM cells (kindly provided by Dr. Roberto
Buccione, CMNS, Italy [28,29]) were grown in DMEM/
F12 (1:1) supplemented with 10% FCS, 2 mM L-glutam-
ine, penicillin and streptomycin at 37°C in 5% CO2.
HT29 cells (ATCC) and A549 cells (ATCC) were grown
in DMEM supplemented with 10% FCS, 2 mM L-glu-
tamine, penicillin and streptomycin, at 37°C in 5% CO2.
MCF7 cells (ATCC) were grown in MEM supplemented
with 10% FCS, non-essential amino acids, insulin 10 μg/
ml (Sigma), NaHCO3 1 mM, penicillin and streptomycin
at 37°C in 5% CO2.
FTI compounds and treatment
The FTI-277 treatment of HeLa and A375MM cell lines
for image analysis and proliferation assays were
performed as previously described [10] with the indi-
cated drug concentrations or, as mock reactions in paral-
lel experiments, with the vehicle DMSO.
PAK phosphorylation inhibitor
IPA3 was added, at the indicated concentration, alone or
combined with FTI-277 or the vehicle (DMSO). Cells
were incubated for the indicated times, as previously de-
scribed [10].
HeLa cells for cell extract preparation were plated in a
6-well plate, left to attach overnight and treated with the
indicated concentration of FTI-277 or vehicle (DMSO).After 48 h, cells were scraped off, collected, washed in
phosphate-buffered-saline (PBS) 1× and lysed in a
modified RIPA buffer [25 mM Tris–HCl pH 7.5,
150 mM NaCl, 1% NP-40, 1% Na-deoxycholate, 0.1%
SDS, 1 mM EDTA, 30 mM β-glycerophosphate, 10 mM
NaF, 5 mM Na orthovanadate, 1 mM PMSF, 1× Protein
tablet inhibitor (Roche)]. Lysates were centrifuged for
10 min, 8000 × g, and then boiled in SDS-loading buf-
fer prior to SDS-PAGE and immunoblot analysis, as
previously described [10].
Immunofluorescence
Immunofluorescence image analysis was performed in
cells plated in 96-well Greiner-Bio-One plates using the
ScanR microscopy platform (Olympus) with a 20× ob-
jective as previously described [10,59]. Briefly, treated
and control samples were plated in 96-well plates and
left to attach for 24 h before drug(s) treatments. Drugs
were added to the medium at the indicated concentra-
tion and incubation continued for the indicated times
(4 h or 48 h). After treatment, cells were washed in PBS
1× and fixed in PBS 1× containing 4% paraformaldehyde
for 10 min. Cells were permeabilized for 30 min in
blocking buffer [0.05% saponin, 0.5% bovine serum albu-
min (BSA), 50 mM NH4Cl and 0.02% NaN3]. Fixed cells
were then incubated with the primary antibody, washed
three times in PBS 1× and incubated with the appropri-
ate fluorescently-conjugated secondary antibody. The
nuclei were stained with Hoechst, prior to being washed
three times in PBS 1× and inspected. High content
image analysis was typically based on data obtained from
at least 3 wells/sample. Image segmentation and analysis
was performed using the inbuilt ScanR analysis software
(Olympus) and based on a mask identifying the nuclei.
The signal intensity values measured for each channel
per sample were based on at least 12 images/well. Sam-
ples were swapped in the plate order in different bio-
logical replicates (typically n ≥ 2) to avoid local intensity
signal drift as previously described [10]. All results are
expressed as mean ± standard deviation (SD).
Statistical analysis
Unpaired T-tests were used to assess differences between
treatment vs. control samples. In the graphs the controls
were normalized to 100 while changes in expression levels
of treatments were analyzed as differences from normal-
ized controls. P-values less than 0.05 were considered sig-
nificant. Statistical analyses were performed using SASW
Language (Release 9.2. Cary, NC, USA; 2002–2008).
Proliferation assays of human cells
MTS-based proliferation assays was performed using
CellTiter 96W AQueous One Solution Cell (Promega)
according to the manufacturer’s protocol. Typically, each
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in a 96-well plate (Falcon). Subsequently, they were
treated with 5 μM FTI-277 and/or IPA3 at a concentra-
tion of 2 μM, 5 μM, or 7 μM. The IPA3 compound was
added at the same time as the FTI-277 or the vehicle
(DMSO) in parallel experiments. The number of living
cells was measured at T = 0 and at T = 48 h. Briefly,
20 μl of Cell Titer was dispensed in each well containing
100 μl medium. The plate was incubated at 37°C in 5%
CO2 sterile chamber for three hours, and the amount of
formazan was measured reading the absorbance at
490 nm with a plate reader (BioTek Instruments). The
results are the mean of three independent experiments.Additional files
Additional file 1: Table S1. The results of chemical profiling of yeast
cells treated with FTase Inhibitor I. The table shows the genes whose
deletion generates a hypersensitive phenotype to 10 μM FTase Inhibitor I
treatment after chemical profiling of approximately 4700 barcoded yeast
deletion strains. Genes discussed in more detail in this paper are
highlighted in orange.
Additional file 2: Table S2. Genes involved in transport and the genes
that respond to chemical stimulus mediate the sensitivity of yeast cells to
FTI. The table shows the biological processes associated with the 64
genes whose deletion generates a hypersensitive phenotype to FTase
inhibitor I. The genes were binned using GO Slim Mapper binning by
Biological Process (SGD, Saccharomyces Genome Database at
yeastgenome.org). Each gene is listed by a gene identifier, the biological
process assigned to the gene by SGD, the relative frequency of genes
that have the same process compared to the total number of genes
considered, and compared to the total number of genes that carry out
that process in the whole yeast genome, and the names of the genes
belonging to each group.
Additional file 3: Figure S1. Cla4-GFP localizes like the wt Cla4 protein
in BY4741 cells. Representative images of exponentially growing BY4741
wt cells carrying the plasmid Cla4-GFP pUG34 treated for 1 h with 10 μM
FTase Inhibitor I (panel FTI) or with vehicle (panel Vehicle) as indicated in
the text in the appropriate selective media. Microscopy inspection and
image acquisition was performed as previously described using a 60×
objective [10].
Additional file 4: Figure S2. A375MM cells are highly sensitive to
20 μM IPA3. A375 MM cells were treated for 48 h with the indicated
compounds as indicated in Figure 5 and in Methods. % is relative to the
vehicle arbitrarily considered as 100%. Error bars are means ± SD of 2
independent experiments calculated from 4 wells/sample.
Additional file 5: Figure S3. Combined treatment of FTI-277 and IPA3
does not induce apoptosis in HeLa and A375MM cells. HeLa and
A375MM cells were treated for 48 h as indicated in Figures 2, 3 and in
Methods, and stained with Hoechst. Olympus ScanR analysis software was
used to calculate the number of apoptotic cells based on the total
intensity Hoechst signal present within the nuclear region as described in
[10]. More than 573 HeLa cells and 73 A375MM cells were counted per
sample in each experiment. The graph represents the relative amount (%)
of apoptotic cells in treated versus vehicle-treated cells, arbitrarily set at
100%. The graph shows the mean ± SD of 2 independent experiments,
each run in triplicate (three wells per condition). Results of t-test are
shown above the graph: ns: no significant deviation from vehicle, p-value
>0.05; * p-value <0.05; ** p-value <0.01.Abbreviations
FTI: Farnesyl-transferase inhibitor; FTase: Farnesyl-transferase;
PAK: P21-activated kinase; PhoPAK: Phosphorylated p21-activated kinase.Competing interests
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